Sargent Bickham Lagudis LLC Vertex Pharmaceuticals Inc Transaction History
Sargent Bickham Lagudis LLC
- $1.22 Billion
- Q4 2022
A detailed history of Sargent Bickham Lagudis LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Sargent Bickham Lagudis LLC holds 202 shares of VRTX stock, worth $92,718. This represents 0.0% of its overall portfolio holdings.
Number of Shares
202
Previous 202
-0.0%
Holding current value
$92,718
Previous $58,000
-0.0%
% of portfolio
0.0%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding VRTX
# of Institutions
1,745Shares Held
227MCall Options Held
1.53MPut Options Held
1.4M-
Capital World Investors Los Angeles, CA28.3MShares$13 Billion1.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.3MShares$10.7 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.78 Billion0.23% of portfolio
-
State Street Corp Boston, MA12MShares$5.5 Billion0.2% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.4MShares$4.79 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $118B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...